FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 	-

ONID APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									

hours per response:

0.5

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BAILEY DON M					2. Issuer Name and Ticker or Trading Symbol OUESTCOR PHARMACEUTICALS INC							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
					QSC 1							Director		10% Owne		ner	
(Last) (First) (Middle)											>	Officer (give title below)			Other (specify below)		
3260 WHIPPLE RD					3. Date of Earliest Transaction (Month/Day/Year) 07/02/2007						Director, Interim President						
(Street)	CITY (0.4507		4. If Amendment, Date of Original Filed (Month/Day/Year)					Line)	6. Individual or Joint/Group Filing (Check Applicable Line)						
UNION	CITY C	CA	94587)	X Form filed by One Reporting Person						
(City)	(\$	State)	(Zip)								Form fil Person	led by More than One Reporting					
		Та	ble I - Non-	Derivat	ive S	ecuritie	s Ac	quired, Di	sposed	of, or Be	neficially	Owned					
		2. Transact Date (Month/Day	Execution Date, (Day/Year) if any		Execution Date,			rities Acquir ed Of (D) (Ins	ed (A) or str. 3, 4 and 5	Securities Form Beneficially (D) of		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Direct I Indirect E str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
						Code V	Amoun	t (A) o	r Price								
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	Code	ansaction Derivative ode (Instr. Securities		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amof Securities Underlying Derivative Secu (Instr. 3 and 4)			ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction (Instr. 4)	on(s)			
Stock Option (Right to Buy) ⁽¹⁾	\$0.44	07/02/2007		A		320,000		(2)	07/01/2017	Common Stock	320,000	\$0.44	320,00	00	D		
Stock Option (Right to	\$0.44	07/02/2007		A		200,000		(3)	07/01/2017	Common Stock	200,000	\$0.44	200,00	00	D		

Explanation of Responses:

- 1. Options were granted under the Questcor Pharmaceuticals, Inc. 2006 Equity Incentive Award Plan.
- 2. Options vest monthly over a 10 month period from the date of grant.
- 3. The option is subject to performance-based vesting based on certain performance criteria set forth in the Questcor Pharmaceuticals, Inc. 2006 Equity Incentive Award Plan. The option has a 10-year term ending July 01, 2017 (or earlier in certain circumstances).

/s/ Don M. Bailey

07/05/2007

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.